CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics

CASI Pharmaceuticals, Inc. (CASI): $2.82

0.04 (+1.44%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add CASI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#92 of 381

in industry

CASI Price/Volume Stats

Current price $2.82 52-week high $4.90
Prev. close $2.78 52-week low $1.45
Day low $2.75 Volume 58,000
Day high $2.98 Avg. volume 33,021
50-day MA $2.61 Dividend yield N/A
200-day MA $2.41 Market Cap 37.57M

CASI Stock Price Chart Interactive Chart >

CASI Stock Summary

  • CASI PHARMACEUTICALS INC's market capitalization of $34,586,096 is ahead of only 11.72% of US-listed equities.
  • For CASI, its debt to operating expenses ratio is greater than that reported by only 0.39% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, CASI PHARMACEUTICALS INC's debt growth rate surpasses just 0% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CASI PHARMACEUTICALS INC, a group of peers worth examining would be UPST, BIGC, VERI, TWOU, and LVOX.
  • Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.

CASI Valuation Summary

  • CASI's price/sales ratio is 0.8; this is 60% lower than that of the median Healthcare stock.
  • Over the past 243 months, CASI's price/sales ratio has gone down 55.2.

Below are key valuation metrics over time for CASI.

Stock Date P/S P/B P/E EV/EBIT
CASI 2023-05-01 0.8 0.8 -0.9 0.3
CASI 2023-04-28 0.9 0.9 -0.9 0.2
CASI 2023-04-27 0.9 0.9 -1.0 0.2
CASI 2023-04-26 0.9 0.9 -0.9 0.2
CASI 2023-04-25 1.1 0.7 -1.5 -0.5
CASI 2023-04-24 1.1 0.7 -1.5 -0.6

CASI Growth Metrics

    The 2 year price growth rate now stands at -82.06%.
  • The 3 year price growth rate now stands at -90.19%.
  • Its 4 year price growth rate is now at 68.93%.
Over the past 33 months, CASI's revenue has gone up $32,875,000.

The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 37.006 -27.886 -27.078
2022-06-30 34.905 -25.222 -32.101
2022-03-31 33.494 -23.079 -31.367
2021-12-31 30.168 -26.842 -36.654
2021-09-30 25.832 -27.233 -45.252
2021-06-30 21.962 -30.203 -51.981

CASI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CASI has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
  • CASI's asset turnover comes in at 0.158 -- ranking 218th of 682 Pharmaceutical Products stocks.
  • DRNA, RARE, and ALNY are the stocks whose asset turnover ratios are most correlated with CASI.

The table below shows CASI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.585 -0.969
2021-03-31 0.139 0.505 -1.192
2020-12-31 0.134 0.372 -1.351
2020-09-30 0.109 0.242 -1.615
2020-06-30 0.101 0.053 -1.638
2020-03-31 0.070 0.052 -2.024

CASI Price Target

For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.45 Average Broker Recommendation 1.25 (Strong Buy)

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CASI as an investment opportunity.

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023.

Yahoo | May 17, 2023

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023. The annual report can be accessed on the Company's investor relations website at https://www.casipharmaceuticals.com/investor-

Yahoo | April 26, 2023

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.

Yahoo | April 26, 2023

Improved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justified

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders would be excited to see that the share price has had a great...

Yahoo | April 17, 2023

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation Merger") has been completed.

Yahoo | March 21, 2023

Read More 'CASI' Stories Here

CASI Price Returns

1-mo 4.83%
3-mo 46.88%
6-mo 44.62%
1-year -18.09%
3-year -89.32%
5-year -95.64%
YTD 57.54%
2022 -77.63%
2021 -72.88%
2020 -4.53%
2019 -23.13%
2018 23.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!